Press Releases

13/02 Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy GL
09/02 Novartis : ESG Data Summary 2025 PU
09/02 Novartis : Update PU
09/02 Novartis : SASB index PU
06/02 Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery GL
06/02 Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery GL
04/02 Novartis: Q4 Earnings Snapshot AQ
04/02 Novartis : Report PU
04/02 Novartis : Earnings Document (q4 2025 investor presentation) PU
04/02 Novartis : Earnings Document (q4 2025 interim financial report en) PU
04/02 Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 GL
30/01 NFL Greats and Novartis Tackle Prostate Cancer Myths at Super Bowl LX, Relax, It's a Blood Test AQ
16/01 Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease GL
15/01 Letter to global governments: A call for bold life sciences investment PU
09/01 Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment GL
09/01 Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment GL
20/12 Novartis and US government reach agreement on lowering drug prices in the US GL
12/12 Novartis breaks ground on flagship manufacturing hub in North Carolina GL
12/12 Market Outlook: Injectable Drug Delivery Industry to Top US$1,034.78 Billion by 2030 AQ
09/12 Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses GL
09/12 1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years GL
25/11 Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS GL
25/11 Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) GL
20/11 Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets GL
19/11 Novartis announces plans to build flagship manufacturing hub in North Carolina GL
No results for this search